OncoGenex/Teva Alter Late-Stage Custirsen Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva and OncoGenex announced changes to the Phase III program of their prostate cancer drug custirsen on the heels of positive data from a competitor.